MARKETS / NYSE / EVH
NYSE · SERVICES-MANAGEMENT SERVICES · LARGE CAP

Evolent Health, Inc. EVH

13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.9B
▼ 26.6% vs FY2024
EPS · FY25
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-75.5%
Net margin · FY25
-28.5%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.9B
Revenue, FY2025 · full 13-year series below
Revenue Net income
0.81.62.43.21.9-0.520132016201920222025
0.81.62.43.21.9-0.52016201920222025

The company lost 28 cents on every revenue dollar this year.

Per share
Diluted EPS, FY2025
EPS
0.40.81.220132016201920222025
0.40.81.22016201920222025

The company pays no cash dividend.

Profitability
-75.5%
Return on equity, FY2025
ROE
4080120-75.5%20132016201920222025
4080120-75.5%2016201920222025
Operating margin-21.9%
Net margin-28.5%
Return on assets-24.1%

Each USD of equity lost 75 cents this year.

Returned to shareholders
USD 40.0M
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacksUSD 40.0M
Share of profit-7.5%
Consecutive raises

USD 40.0M in buybacks went back to shareholders in a year without profit.

Growth
+15.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+11.5%
+15.2%
+34.5%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
Shares outstanding, FY2025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.9B
total assets, end of FY2025
Total assetsUSD 1.9B
EquityUSD 415.2M
CashUSD 151.9M
Gross debtUSD 970.5M
Net debtUSD 818.7M
Current ratio1.31×

Net debt stands at 197% of equity.

History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
1.9
2.6
2.0
1.4
0.9
0.9
0.7
0.6
0.4
0.3
0.1
0.0
0.0
Operating income $B
−0.4
−0.0
−0.1
0.0
−0.0
−0.3
−0.3
−0.0
−0.1
−0.2
−0.0
0.0
−0.0
EBITDA $B
−0.3
0.1
0.1
0.1
0.0
−0.2
−0.2
−0.0
−0.0
−0.2
−0.0
0.0
−0.0
Income tax $B
−0.0
−0.0
−0.1
−0.0
0.0
−0.0
−0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
Net income $B
−0.5
−0.1
−0.1
−0.0
−0.0
−0.3
−0.3
−0.1
−0.1
−0.2
0.3
−0.0
0.0
EPS, diluted $
·
·
·
·
·
·
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−75.5
−6.0
−11.7
−2.5
−5.7
−43.2
−29.5
−4.9
−7.1
−23.6
102.7
·
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
37 of 37
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed